• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

POLL: Which September FDA Approval Are You Looking Forward To?

Poll

Click here to answer this week's poll.

Which September FDA Approval Are You Looking Forward To?

Revance's daxibotulinumtoxinA for glabbelar lines; PDUFA September 8, 2022
Bristol Myers Squibb's deucravacitinib for psoriasis; PDUFA September 10, 2022
Sanofi/Regneron's dupilumab for prurigo nodularis; PDUFA September 30, 2022
Related Content
POLL: Would You Consider Utilizing Virtual Reality in Your Practice or to Further Your Education?

POLL: Would You Consider Utilizing Virtual Reality in Your Practice or to Further Your Education?

Article
What Conferences Are You Planning to Attend in Quarter 2 of 2024?

What Conferences Are You Planning to Attend in Quarter 2 of 2024?

Article
POLL: What Topic Do You Most Want Us to Cover at the American Academy of Dermatology Annual Meeting?

POLL: What Topic Do You Most Want Us to Cover at the American Academy of Dermatology Annual Meeting?

Article
POLL: Are You Attending the American Academy of Dermatology Annual Meeting?

POLL: Are You Attending the American Academy of Dermatology Annual Meeting?

Article
POLL: Which of These Rare Dermatologic Diseases Have You Encountered in Your Practice?

POLL: Which of These Rare Dermatologic Diseases Have You Encountered in Your Practice?

Article
Surveying Our Readers: What Are Your Thoughts on the New AAD Acne Guidelines?

Surveying Our Readers: What Are Your Thoughts on the New AAD Acne Guidelines?

Article
© 2024 MJH Life Sciences

All rights reserved.